JUNS Key Statistics, Chart & Performance
The current stock price of JUNS is 1.14 USD. In the past month the price decreased by -16.18%. In the past year, price decreased by -85.37%.
JUNS Latest News, Press Relases and Analysis
JUNS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About JUNS
Company Profile
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Company Info
JUPITER NEUROSCIENCES INC
1001 North US HWY 1, Suite 504
Palm Beach Gardens FLORIDA US
Employees: 4
Phone: 15614066154
JUPITER NEUROSCIENCES INC / JUNS FAQ
What does JUPITER NEUROSCIENCES INC do?
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
What is the stock price of JUPITER NEUROSCIENCES INC today?
The current stock price of JUNS is 1.14 USD. The price decreased by -6.56% in the last trading session.
Does JUPITER NEUROSCIENCES INC pay dividends?
JUNS does not pay a dividend.
What is the ChartMill technical and fundamental rating of JUNS stock?
JUNS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is JUPITER NEUROSCIENCES INC (JUNS) stock traded?
JUNS stock is listed on the Nasdaq exchange.
Would investing in JUPITER NEUROSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on JUNS.
What is the market capitalization of JUNS stock?
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 39.25M USD. This makes JUNS a Nano Cap stock.
JUNS Technical Analysis
JUNS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to JUNS. Both the profitability and financial health of JUNS have multiple concerns.
JUNS Financial Highlights
Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 46.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -148.65% | ||
| ROE | -440.16% | ||
| Debt/Equity | 0.11 |
JUNS Forecast & Estimates
7 analysts have analysed JUNS and the average price target is 25.5 USD. This implies a price increase of 2136.84% is expected in the next year compared to the current price of 1.14.